complement-dependent lymphocytotoxic crossmatching became a contraindication to renal transplantation. However, cell-based assays are unable to detect low DSA levels or DSAs that do not activate complement. Thus, patients who are complement-dependent crossmatch-negative may still harbor DSAs. 3 Compared with complement-dependent T-cell crossmatching, solid-phase immunoassays are more sensitive, 4, 5 detecting not only low class I antibody levels, but also antibodies against class II antigens and class I and class II allele-specific antibodies. 5, 6 Moreover, solid-phase immunoassays are semi-quantitative, permitting the categorization of DSA levels. 5 The phase III Belatacept Evaluation of Nephroprotection and
Efficacy as First-Line Immunosuppression Trial (BENEFIT) and BENEFIT-Extended Criteria Donors (BENEFIT-EXT) studies evaluated belatacept, a selective T-cell costimulation blocker approved worldwide to prevent kidney transplant rejection in adults. 7 Kidney transplant recipients enrolled to these similarly designed studies
were T-cell lymphocytotoxic crossmatch-negative (determined locally). However, subsequent testing at a central facility of stored sera via solid-phase flow cytometry and single-antigen bead assay revealed that a subset of patients did possess preexisting DSAs.
Importantly, the results from these prespecified exploratory analyses were not intended for use as a requirement for study entry or for patient management (ie, centers were unaware of assay results prior to transplantation). The present post hoc analyses examined the effect of belatacept-based and cyclosporine-based immunosuppression on MFI in the subsets of BENEFIT and BENEFIT-EXT participants with preexisting DSAs. Efficacy and safety at 7 years (84 months) posttransplant in these patients were also evaluated.
| ME THODS

| Study design
BENEFIT (NCT00256750) and BENEFIT-EXT (NCT00114777) were 3-year, international, partially blinded, randomized phase III studies. 8, 9 Patients undergoing primary transplant with T-cell panel reactive antibodies (PRA) ≥50% or those undergoing re-transplantation with T-cell PRA ≥30% were excluded, as were patients with a locally determined positive T-cell crossmatch with the intended donor.
Patients in BENEFIT received a living or standard-criteria deceased donor kidney. Patients in BENEFIT-EXT received an extendedcriteria donor kidney.
Participants were initially randomized (1:1:1) to receive belatacept more intense (MI)-based, belatacept less intense (LI)-based, or cyclosporine-based immunosuppression for 3 years, 8,9 but a protocol amendment allowed them to continue randomized treatment beyond 3 years. 10, 11 In addition to randomized treatment, patients received basiliximab induction, mycophenolate mofetil, and corticosteroids.
These studies were conducted in accordance with Good Clinical
Practice guidelines and the principles outlined in the Declaration of Helsinki. The institutional review boards/ethics committees at participating centers approved the study protocols. All patients provided written informed consent.
| Assessments
The presence of HLA antibodies was assessed in all randomized, transplanted patients at baseline (day 0, the day of transplant), at months 6, 12, 24, 36, 48, 60, and 84, and at the time of clinically suspected episodes of acute rejection. Antibody screening was performed centrally at Emory University using solid-phase flow cytometry screening (FlowPRA, One Lambda, Inc., Canoga Park, CA). HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQA, and -DQB1 antigens were identified by molecular typing methods, typically to the two-digit (low resolution)
level. HLA-DP typing was not performed, since no study participant had HLA-DP antibodies. Sera from patients with anti-HLA antibodies were subsequently analyzed using Luminex single-antigen bead assay (One Lambda, Inc.) to determine antibody class specificity, the presence/ absence of DSAs, and the mean fluorescence intensity (MFI) of any DSAs present. Sera were not pretreated or diluted prior to singleantigen bead testing. Since this was a post hoc study and because there are no established clinical thresholds for preexisting DSA MFI levels, we wanted to be conservative, considering any patient with DSA MFI levels ≥1000 as preexisting DSA-positive. To minimize variation due to lot/technician differences, all samples-irrespective of the time at which they were drawn-were tested and analyzed at the same time. Singleantigen testing was performed using a modified technique employing a biotin-conjugated secondary antibody followed by phycoerythrinconjugated streptavidin. An MFI value of 1000 in this assay corresponds to a slightly lower MFI value than in the nonmodified (standard) assay.
Details on our modified technique are described in Sullivan et al.
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The following were analyzed in each study: death or graft loss, renal function (six-variable Modification of Diet in Renal Disease equation 13 ), and acute rejection (central biopsy-proven rejection that was clinically suspected for protocol-defined reasons or clinically suspected for other reasons and treated).
| Statistics
Patients were analyzed according to the intent-to-treat principle.
Descriptive statistics were used to summarize MFI from baseline (pretransplant) to month 24 in the subsets of patients from each study with preexisting DSAs. Any DSA MFI value ≥1000 at baseline was considered positive. Time to death or graft loss was assessed in evaluable patients (patients known to be alive at month 84 or known to have died or experienced graft loss by month 84) and described using Kaplan-Meier event rates. The method of Kaplan-Meier was used to determine time to death or graft loss from randomization to month 84 in the cohorts of patients in each study who did and did not have preexisting DSAs. These cohorts were compared using hazard ratios (HRs) and 95% confidence intervals (CIs), which were calculated via Cox regression; no adjustment was made for multiplicity. Kaplan-Meier cumulative event rates were used to summarize the incidence of acute rejection. Descriptive statistics were used to summarize renal function (month 1 to month 84).
| RE SULTS
| BENEFIT
In BENEFIT, 4.6% (10/219), 4.9% (11/226), and 6.3% (14/221) of patients randomized to belatacept MI, belatacept LI, and cyclosporine, respectively, had DSAs prior to transplant. The HLA class specificity of preexisting DSAs was similar across treatment arms, with the majority being class I ( Table 1 
Reported cause of ESRD, n (%) The HR for the comparison of patients with versus without preexisting DSAs was 1.47 (95% CI 0.68-3.18; P = .33) (Figure 2A ).
In the subset of patients with preexisting DSAs, mean estimated GFR (as observed) between month 3 and month 84 remained essentially stable for those randomized to belatacept MI, increased for those randomized to belatacept LI, and decreased for those randomized to cyclosporine ( Figure 3A 
| BENEFIT-EXT
In BENEFIT-EXT, 6.0% (11/184), 5.7% (10/175), and 9.2% (17/184) of patients randomized to belatacept MI, belatacept LI, and cyclosporine, respectively, had DSAs prior to transplant. The HLA class specificity of preexisting DSAs was similar across treatment arms, with the majority being class I (Table 2) . Compared with the other two treatment arms, proportionally more patients with preexisting DSAs assigned to belatacept MI had baseline PRA <20% and proportionally fewer patients with preexisting DSAs assigned to cyclosporine were male ( Table 2 ). The average baseline MFI of HLA DSAs in belatacept MI-treated, belatacept LI-treated, and cyclosporine-treated patients were 4454 (range, 1900-15 000), 5495 (900-15 000), and 6204 (1000-18 000), respectively.
Thirteen HLA DSAs (class I, n = 9; class II, n = 4) were detected in the 11 belatacept MI-treated patients with preexisting DSAs. MFI 
| D ISCUSS I ON
When the BENEFIT and BENEFIT-EXT studies were undertaken, it was standard practice to assess donor-recipient histocompatibility using only cell-based cytotoxicity assays. When retrospectively examining stored patient sera using solid-phase assays, which are more sensitive than T-cell lymphocytotoxic crossmatching, we discovered that 5.3% of BENEFIT participants and 7.0% of BENEFIT-EXT partici- Preexisting DSA HLA class specificity, n (%) satisfied all eligibility criteria. Although there was space on the form for investigators to provide numerical results for the highest and most recent PRA percentages, they were not required to do so. Thus, the PRA percentage is missing for some study participants.
preexisting DSAs did not impact graft survival over 84 months in either BENEFIT or BENEFIT-EXT; Kaplan-Meier estimated rates of death or graft loss at month 84 were similar in the subgroups of patients with and without preexisting DSAs. In addition to being non-complement-fixing (and thus escaping detection via cytotoxic T-cell crossmatching), it is possible that these preexisting DSAs were also "less pathogenic." Unfortunately, due to the small sample sizes in both BENEFIT and BENEFIT-EXT, it was not possible to examine the effects of individual patients' treatment on either time to death or time to graft loss in patients with preexisting DSAs.
Renal function over 7 years of follow-up was either stable or improved in belatacept-treated patients with preexisting DSAs. In 14 The cumulative event rates of acute rejection in the subsets of patients with preexisting DSAs randomized to belatacept MI (25.0%) and cyclosporine (19.1%) in BENEFIT-EXT were similar to the rates seen in the overall study population (belatacept MI, 21.1%; cyclosporine, 17.3%). However, the rate of acute rejection was numerically higher in the subset of BENEFIT-EXT participants with preexisting DSAs randomized to belatacept LI compared with the overall population of belatacept LI-treated patients at 7 years posttransplant (40.0% vs. 19.5%). 15 These discrepant results could be attributable to the limited sample size.
These analyses are limited by the fact that they were conducted post hoc. As a consequence, the numbers of patients analyzed were small, and MFI was not available at all time points for all individuals.
In addition, patients were not randomized according to preexisting DSA status. Moreover, patient sera were only subjected to single- It is intriguing to speculate that belatacept may have the potential to reduce HLA antibodies in sensitized individuals awaiting a kidney transplant, but additional studies are needed to test this hypothesis.
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